Management of HIV-infected children in Africa: Progress and challenges

Archives of Disease in Childhood

Volumn 96, Issue 10, 2011, Pages 911-915

  Bland, Ruth M ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

AFRICA; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; CLINICAL PRACTICE; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSLIPIDEMIA; HALLUCINATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LABORATORY DIAGNOSIS; LABORATORY TEST; LACTIC ACIDOSIS; LIPOATROPHY; MALNUTRITION; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; TUBERCULOSIS;

EID: 80052847620     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.193789     Document Type: Review

References (47)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global Aids Epidemic. 2010. http://issuu.com/unaids/docs/unaids-globalreport-2010/9? mode=a-p(accessed 29 Dec 2010).
2. World Health Organization. Paediatric HIV and Treatment of Children Living with HIV. Geneva: WHO, 2010. http://www.who.int/hiv/topics/paediatric/en/ index.html (accessed 4 May 2011).
3. KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008;49:523-31.
4. Cherutich P, Inwani I, Nduati R, et al. Optimizing paediatric HIV care in Kenya: challenges in early infant diagnosis. Bull World Health Organ 2008;86:155-60. (Pubitemid 351213719)
5. Kiboneka A, Wangisi J, Nabiryo C, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 2008;22:2493-9.
6. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of anti retroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008;8:477-89. (Pubitemid 352005822)
7. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61. (Pubitemid 28115000)
8. Newell ML, Coovadia H, Cortina-Borja M, et al.; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:1236-43.
9. Inwani I, Mbori-Ngacha D, Nduati R, et al. Performance of clinical algorithms for HIV-1 diagnosis and antiretroviral initiation among HIV-1-exposed children aged less than 18 months in Kenya. J Acquir Immune Defic Syndr 2009;50:492-8.
10. World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach: 2010 Revision. http://www.who.int/hiv/pub/paediatric/ infants2010/en/(accessed 4 May 2011).
11. Fischer A, Lejczak C, Lambert C, et al. Simple DNA extraction method for dried blood spots and comparison of two PCR assays for diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda. J Clin Microbiol 2004;42:16-20.
12. Rouet F, Ekouevi DK, Chaix ML, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005;43:2709-17. (Pubitemid 40827943)
13. Rouet F, Sakarovitch C, Msell ati P, et al.; Abidjan ANRS 049 Ditrame Study Group. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics 2003;112:e289.
14. Sherman GG, Stevens G, Jones SA, et al. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005;38:615-17. (Pubitemid 40524486)
15. Rollins N, Little K, Mzolo S, et al. Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening. AIDS 2007;21:1341-7. (Pubitemid 46883489)
16. Jones SA, Sherman GG, Varga CA. Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa. AIDS Care 2005;17:466-70. (Pubitemid 40663206)
17. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298:1888-99. (Pubitemid 350005233)
18. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med 2008;5:e73.
19. Dunn D,; HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003;362:1605-11.
20. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV infected children in resource-limited settings: a meta-analysis. AIDS 2008;22:97-105.
21. El-Sadr WM, Lundgren JD, Neaton JD, et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
22. Violari A, Cotton MF, Gibb DM, et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44.
23. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-47. (Pubitemid 46089674)
24. Cooke GS, Little KE, Bland RM, et al. Need for timely paediatric HIV treatment within primary health care in rural South Africa. PLoS ONE 2009;4:e7101.
25. Meyers T, Moultrie H, Naidoo K, et al. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis 2007;196(Suppl 3):S474-81.
26. Davies MA, Boulle A, Fakir T, et al. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr 2008;8:34.
27. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90. (Pubitemid 44200639)
28. Kekitiinwa A, Lee KJ, Walker AS, et al.; Collaborative HIV Paediatric Study (CHIPS) Steering Committe; Mulago Cohort Team. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr 2008;49:384-92.
29. Mugyenyi P, Walker AS, Hakim J, et al.; DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010;375:123-31.
30. O'Brien DP, Sauvageot D, Zachari ah R, et al.; Medecins Sans Frontieres. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006;20:1955-60. (Pubitemid 44427613)
31. Janssen N, Ndirangu J, Newell ML, et al. Successful paediatric HIV treatment in rural primary care in Africa. Arch Dis Child 2010;95:414-21.
32. Fenner L, Brinkhof MW, Keiser O, et al.; International epidemiologic Databases to Evaluate AIDS in Southern Africa. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010;54:524-32.
33. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort Profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol 2011;40:318-26.
34. Ndirangu J, Newell ML, Tanser F, et al. Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? AIDS 2010;24:593-602.
35. Ferrand RA, Corbett EL, Wood R, et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009;23:2039-46.
36. Nachega JB, Hislop M, Nguyen H, et al. Anti retroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009;51:65-71.
37. Newton SM, Brent AJ, Anderson S, et al. Paediatric tuberculosis. Lancet Infect Dis 2008;8:498-510. (Pubitemid 352001412)
38. Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 2006;118:e1350-9.
39. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010;375:1920-37.
40. Pai M, Riley LW, Colford JM, Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76.
41. Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010;201:1121-31.
42. Yotebieng M, Van Rie A, Moultrie H, et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tubercul osi s treatment. AIDS 2010;24:1341-9.
43. Heikens GT, Bunn J, Amadi B, et al.; Blantyre Working Group. Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. Lancet 2008;371:1305-7. (Pubitemid 351491320)
44. Callens SF, Shabani N, Lusiama J, et al.; SARA team. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo. Pediatr Infect Dis J 2009;28:35-40.
45. World Health Organization. Guidelines for an Integrated Approach to Nutritional Care of HIV-Infected Children (6 Months-14 Years). Geneva: WHO, 2009. http://www.who.int/nutrition/publications/hivaids/9789241597524/en/ (accessed 4 May 2011).
46. Mubiana-Mbewe M, Bolton-Moore C, Banda Y, et al. Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia. Trop Med Int Health 2009;14:1190-8.
47. Riordan A, Tan T, McMaster P. How do children with HIV present in Northwest England and North Wales? [abstract G30]. Arch Dis Child 2009;95(Suppl 1):A30.